Citius Pharma reports FY2022 net loss $33.6M; cash $41.7M, I/ONTAK PDUFA July 2023

Citius Pharmaceuticals, Inc.

Net loss $33.6M ($0.23/shr) vs $23.1M ($0.23/shr) prior year; R&D expenses up $5.5M to $17.7M.
Cash and equivalents $41.7M as of Sept 30, 2022; estimated runway through December 2023.
I/ONTAK BLA accepted by FDA; PDUFA target action date set for July 28, 2023.
Mino-Lok Phase 3: 169 patients enrolled, 72 of 92 failure events achieved, 17 patients pending.
Halo-Lido Phase 2b enrollment ongoing; data readout expected in second half 2023.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Citius Pharmaceuticals, Inc. reported the fiscal full year ended September 30, 2022 results: net income $33.6 million, EPS ($0.23) per share.

Period: the fiscal full year ended September 30, 2022
Net income: $33.6 million
EPS: ($0.23) per share
Result: reported results

Exact text from the filing

Net loss was $33.6 million, or ($0.23) per share for the full year ended September 30, 2022 compared to a net loss of $23.1 million, or ($0.23) per share for the full year ended September 30, 2021.

View on SEC.gov

Browse all earnings releases →

Citius Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-22-082228

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.